Bicara Therapeutics Inc.
BCAX
Analytical Summary
Bicara Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.
4-Year Financial Trajectory
AnnualBullish Indicators
- No bullish signals detected.
Bearish Risks
- Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| EPS Growth YoY (%) |
37.8%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
95.5%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — |
| Net Income Growth YoY (%) |
-102.9%
Weak
Weak
Year-over-year change in net income |
-30.8%
Weak
Weak
Year-over-year change in net income |
— | — |
| FCF Growth YoY (%) |
56.0%
Excellent
Excellent
Year-over-year change in free cash flow |
94.4%
Excellent
Excellent
Year-over-year change in free cash flow |
— | — |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Effective Tax Rate (%) (%) |
-0.2%
Excellent
↓
Excellent
Declining
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
-0.3%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
-0.0%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— |
| FCF / Net Income (x) |
0.78x
Caution
↓
Caution
Declining
Free cash flow relative to reported net income
Optimal:
> 1x
|
1.10x
Fair
Fair
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.89x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Return on Invested Capital (%) |
-38.8%
Weak
↓
Weak
Declining
Return earned on debt + equity capital invested
Optimal:
> 10%
|
-16.8%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
26.8%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
| Return on Capital (%) (%) |
-36.1%
Weak
↓
Weak
Declining
Operating profit relative to total assets
Optimal:
> 10%
|
-16.2%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
-17.0%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— |
| Return on Common Equity (%) (%) |
-34.4%
Weak
↓
Weak
Declining
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-329%)
|
-13.8%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-192%)
|
34.9%
Excellent
Excellent
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+133%)
|
— |
Secondary lens
Benchmark Lens
Compare BCAX against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare BCAX against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for BCAX
No bullish signals detected
Return on Common Equity (%) is in the bottom quartile
Percentile Rankings
How BCAX compares to all companies
Peer Comparison
BCAX vs similar peers
Compare BCAX with peers
Stack BCAX against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 4 years · 14 quarters